{"id":989,"date":"2023-09-13T10:45:28","date_gmt":"2023-09-13T09:45:28","guid":{"rendered":"https:\/\/services.nhslothian.scot\/diabetesservice\/?p=989"},"modified":"2023-09-13T10:44:44","modified_gmt":"2023-09-13T09:44:44","slug":"new-updated-primary-care-prescribing-guidance-for-adults-with-type-2-diabetes","status":"publish","type":"post","link":"https:\/\/services.nhslothian.scot\/diabetesservice\/2023\/09\/13\/new-updated-primary-care-prescribing-guidance-for-adults-with-type-2-diabetes\/","title":{"rendered":"New updated Primary Care Prescribing Guidance for Adults with Type 2 Diabetes"},"content":{"rendered":"\n

A new updated \u201cOral Anti-Diabetic Therapy Guidelines for Type 2 Diabetes Mellitus\u201d prescribing algorithm<\/a> has been developed. This is very similar to the algorithm published in 2021.<\/p>\n\n\n\n

\"\"<\/a><\/figure>\n\n\n\n

<\/a>The main differences are:<\/p>\n\n\n\n

 1.  Prescribing of SGLT-2 inhibitors is simplified with Dapagliflozin replacing Empagliflozin\/Canagliflozin.<\/p>\n\n\n\n

2. There is an increased focus on cardiorenal protection. In essence, for people with cardiac and\/or renal disease, we are recommending that Dapagliflozin is commenced automatically<\/em> after Metformin therapy is established, irrespective of HbA1c. In the old guideline, an SGLT2 inhibitor was recommended as 2nd<\/sup> line therapy only if HbA1c was above target.<\/p>\n\n\n\n

The Lothian Diabetes MCN prescribing algorithm was previously introduced as a simplified version of the ADA\/EASD guidelines in April 2021 to support primary care prescribing of oral anti-diabetic therapies in adults.<\/p>\n\n\n\n

Further advice is available from the three diabetes centres in Lothian, through their advice email services and at the following links:<\/p>\n\n\n\n

SJH    Clinadvdiab@nhslothian.scot.nhs.uk<\/a> <\/p>\n\n\n\n

WGH  WGH.DiabeticAdvice@nhslothian.scot.nhs.uk<\/a> <\/p>\n\n\n\n

RIE     RIE.DiabetecAdvice@nhslothian.scot.nhs.uk<\/a> <\/p>\n\n\n\n

Supplementary Information for Lothian Diabetes MCN Type 2 Diabetes Prescribing Guidance for Primary Care (FAQ).<\/a><\/p>\n\n\n\n

For MCN updates regarding GLP-1 shortages please visit Prescribing Information \u2013 Diabetes Managed Clinical Network (nhslothian.scot)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

A new updated “Oral Anti-Diabetic Therapy Guidelines for Type 2 Diabetes Mellitus” prescribing algorithm has been developed. This is very similar to the algorithm published in 2021. The main differences are:  1.  Prescribing of SGLT-2 inhibitors is simplified with Dapagliflozin replacing Empagliflozin\/Canagliflozin. 2. There is an increased focus on cardiorenal protection. In essence, for people<\/p>\n","protected":false},"author":282,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"class_list":["post-989","post","type-post","status-publish","format-standard","hentry","category-uncategorised"],"rttpg_featured_image_url":null,"rttpg_author":{"display_name":"wenyizhou","author_link":"https:\/\/services.nhslothian.scot\/diabetesservice\/author\/wenyizhou\/"},"rttpg_comment":0,"rttpg_category":"Uncategorised<\/a>","rttpg_excerpt":"A new updated “Oral Anti-Diabetic Therapy Guidelines for Type 2 Diabetes Mellitus” prescribing algorithm has been developed. This is very similar to the algorithm published in 2021. The main differences are:  1.  Prescribing of SGLT-2 inhibitors is simplified with Dapagliflozin replacing Empagliflozin\/Canagliflozin. 2. There is an increased focus on cardiorenal protection. In essence, for people","_links":{"self":[{"href":"https:\/\/services.nhslothian.scot\/diabetesservice\/wp-json\/wp\/v2\/posts\/989","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/services.nhslothian.scot\/diabetesservice\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/services.nhslothian.scot\/diabetesservice\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/services.nhslothian.scot\/diabetesservice\/wp-json\/wp\/v2\/users\/282"}],"replies":[{"embeddable":true,"href":"https:\/\/services.nhslothian.scot\/diabetesservice\/wp-json\/wp\/v2\/comments?post=989"}],"version-history":[{"count":2,"href":"https:\/\/services.nhslothian.scot\/diabetesservice\/wp-json\/wp\/v2\/posts\/989\/revisions"}],"predecessor-version":[{"id":1012,"href":"https:\/\/services.nhslothian.scot\/diabetesservice\/wp-json\/wp\/v2\/posts\/989\/revisions\/1012"}],"wp:attachment":[{"href":"https:\/\/services.nhslothian.scot\/diabetesservice\/wp-json\/wp\/v2\/media?parent=989"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/services.nhslothian.scot\/diabetesservice\/wp-json\/wp\/v2\/categories?post=989"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}